前列腺癌
聚ADP核糖聚合酶
医学
DNA损伤修复
精密医学
PARP抑制剂
癌症
临床试验
个性化医疗
阉割
癌症研究
肿瘤科
DNA修复
内科学
生物信息学
DNA
生物
聚合酶
病理
遗传学
作者
Chenyang Xu,Shanhua Mao,Hanqiang Jiang
出处
期刊:Methods in molecular biology
日期:2020-01-01
卷期号:: 75-89
被引量:2
标识
DOI:10.1007/978-1-0716-0904-0_7
摘要
Prostate cancer (PCa) is one of the common malignancies in male adults. In the era of precision medicine, many other novel agents targeting advanced prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), are currently being evaluated. Among all these candidate therapies, poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage response (DDR) pathway has proven improving survival outcomes in clinical trials. In this review, we focus on recent advances in biology and clinical implication of DDR pathway and aim to discuss the latest results in advanced prostate cancer, especially mCRPC.
科研通智能强力驱动
Strongly Powered by AbleSci AI